These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 20297875

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anemia and cardiovascular risk in the patient with kidney disease.
    Fishbane S.
    Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
    [Abstract] [Full Text] [Related]

  • 7. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S.
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [Abstract] [Full Text] [Related]

  • 8. Erythropoietin in cancer patients.
    Glaspy JA.
    Annu Rev Med; 2009 Mar; 60():181-92. PubMed ID: 18980468
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
    Doss S, Schiller B.
    Nephrol Nurs J; 2010 Mar; 37(6):617-26. PubMed ID: 21290916
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Role of renal anemia in progression of chronic kidney disease].
    Racki S, Maleta I.
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
    Locatelli F, Gascón P.
    Oncologist; 2009 Sep; 14 Suppl 1():57-62. PubMed ID: 19762517
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
    Hollingsworth K, Romney MC, Crawford A, McAna J.
    J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
    [Abstract] [Full Text] [Related]

  • 19. Erythropoiesis-stimulating agents and heart failure.
    Lipšic E, van der Meer P, van Veldhuisen DJ.
    Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
    [Abstract] [Full Text] [Related]

  • 20. [Erythropoesis-stimulating agents: past, present and future].
    Kes P, Basić-Jukić N.
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.